Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
77.58
-0.26 (-0.33%)
At close: May 23, 2025, 4:00 PM
77.70
+0.12 (0.15%)
After-hours: May 23, 2025, 7:56 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.07
Revenue / Employee
$852,293
Employees
75,000
Market Cap
194.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
MRK News
- 2 days ago - Merck: Defensive Yield Meets Long-Term Optionality - Seeking Alpha
- 3 days ago - Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025 - Business Wire
- 3 days ago - Merck: Undervalued In Light Of Key Risks - Seeking Alpha
- 3 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 3 days ago - Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference - Business Wire
- 4 days ago - Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Business Wire
- 6 days ago - I'm Putting Cash To Work: 2 Rock-Solid Dividends At Bargain Prices - Seeking Alpha
- 9 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire